• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice

Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice

by Elena Iemma | Jun 16, 2022

Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice
Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory

Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory

by Elena Iemma | Sep 13, 2021

Novel immunogen design elicits increased protection against avian H7N9 influenza that is associated with mobilization of seasonal influenza T cell memory
Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge

Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge

by Annie De Groot | Sep 30, 2020

Immune engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge
Structure-guided Immunogen Design: Modulating B cell and T cell Immunogenicity of First and Second Generation H7N9 Vaccines

Structure-guided Immunogen Design: Modulating B cell and T cell Immunogenicity of First and Second Generation H7N9 Vaccines

by Annie De Groot | Mar 20, 2019

ACVR immune engineering poster 2019_20Mar2019_930am
T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response

T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response

by Annie De Groot | Aug 15, 2018

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline